Mesh Bio
Singapore-headquartered digital health company founded in 2018 that builds AI-powered digital twin predictive analytics for chronic disease management, selling its DARA platform and HSA-cleared HealthVector Diabetes SaMD to hospitals, clinics, and laboratories across Southeast Asia.
- Company typePrivate
- Founded2018
- HeadquartersBukit Merah, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Mesh Bio does
Mesh Bio is a Singapore-headquartered digital health company founded in 2018 by Andrew Wu (CEO) and Arsen Batagov (CTO). The company develops AI-powered predictive analytics software for chronic disease management, with its core DARA® platform automating health screening workflows, generating risk-stratified clinical reports, and integrating into hospital electronic health record systems via Epic and FHIR/HL7 standards. Underlying the platform is a proprietary digital twin technology that uses metabolic flux analysis to model patient-level disease trajectories and is validated across 7,000+ clinical scenarios against datasets such as the SingHealth Diabetes Registry and the NHG Chronic Disease Management Datamart.
The company has expanded into regulated medical devices with HealthVector® Diabetes, an HSA-approved Class B Software as a Medical Device that predicts 3-year chronic kidney disease risk in Type 2 diabetes patients. Mesh Bio sells primarily to enterprise healthcare providers — hospitals, health screening centers, clinics, and diagnostic laboratories — through direct enterprise sales on a subscription SaaS model, supplemented by implementation pilots funded in part by Singapore's National Health Innovation Centre (NHIC). The company reports 40+ healthcare group customers and 300,000+ patients assessed across Singapore, Indonesia, Malaysia, the Philippines, and Hong Kong, with named enterprise accounts including Parkway Shenton, Fullerton Health, PT Pramita, Singapore General Hospital, and Tan Tock Seng Hospital.
Mesh Bio holds ISO 27001 (information security) and ISO 13485 (medical device quality management) certifications and has raised approximately $5.3 million in disclosed funding across a 2021 seed round, a 2023 East Ventures investment, and a $3.5 million Series A in January 2024, with backers including East Ventures, Elev8.vc, Seeds Capital, Citrine Capital, and Tael Partners. The business model combines subscription software licensing for DARA with regulated-device commercialization via HealthVector Diabetes, positioning the company at the intersection of enterprise health IT and clinical decision support across Southeast Asia.
Mesh Bio firmographics
Firmographics- Name
- Mesh Bio
- Legal name
- Mesh Bio Pte. Ltd.
- Website
- https://meshbio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Singapore-headquartered digital health company founded in 2018 that builds AI-powered digital twin predictive analytics for chronic disease management, selling its DARA platform and HSA-cleared HealthVector Diabetes SaMD to hospitals, clinics, and laboratories across Southeast Asia.
- Ownership category
- akta.pro rank
Mesh Bio industry classification
Industry- Product category
- Digital Health Analytics Software
- NAICS
- Software Publishers (5132), Computer Systems Design and Related Services (54151)
- SIC
- Services-Health Services (8000), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- AI/Analytics for RPM (Risk Stratification, Alerts, Predictive) (HLACAFAM)
- akta.pro secondary industry
- Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension) (HLACAPAD)
Keywords
Where Mesh Bio is headquartered
LocationHeadquarters
- HQ city
- Bukit Merah
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
Mesh Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Software/SaaS Subscription: Mesh Bio provides AI-powered health analytics software to healthcare providers on a subscription basis. The platform is deployed at healthcare groups across Asia, with pricing likely structured around the number of patients assessed or healthcare providers served.
- Regulatory-approved Medical Device: HealthVector Diabetes is approved as a Class B Software as a Medical Device (SaMD) by HSA Singapore, allowing deployment in clinical settings with regulatory compliance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise B2B pricing for healthcare providers |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Mesh Bio product offering
Product offeringCore offering
Mesh Bio sells an AI-powered health intelligence software platform called DARA® that delivers predictive analytics, risk stratification, and clinical workflow automation to healthcare providers for chronic disease management. The company also offers HealthVector® Diabetes, an HSA-approved Class B Software as a Medical Device that predicts 3-year onset risk of chronic kidney disease in Type 2 diabetes patients using metabolic digital twin technology.
Product overview
Mesh Bio's product portfolio is organised as a platform-plus-modules architecture. The flagship platform is DARA® (Health Intelligence Platform), which provides predictive analytics and clinical workflow automation for healthcare providers. DARA® comprises three integrated modules: the Health Screening Module (automated report generation and risk scoring), the Result Interpretation Module (digitised specialist result workflows), and the Referral Module (digital referral management with tracking). The HealthVector® Diabetes sub-brand is a regulatory-approved (HSA Class B SaMD) digital twin product for predicting 3-year CKD risk in Type 2 diabetes patients, which also operates as a standalone module within the DARA® ecosystem. The platform collectively covers chronic diseases including diabetes, cardiovascular disease, hypertension, chronic kidney disease, and MAFLD, and is deployed across Singapore, Malaysia, Hong Kong, and Indonesia.
Differentiator
Problem solved
Functional benefit
Brands
- DARA: Predictive analytics and clinical workflow automation solution for healthcare providers featuring automated health screening reports, risk stratification, clinical decision support, and integration with existing workflows
- HealthVector Diabetes
Products and services
- DARA® Health Intelligence Platform DARA® is the core health intelligence platform providing predictive analytics and clinical workflow automation for healthcare providers, supporting health screening, result interpretation, and referral management. It generates automated personalised clinical reports, performs risk stratification across cardiovascular disease, diabetes, hypertension, chronic kidney disease, and MAFLD using a portfolio of clinically validated risk calculators covering 7,000+ clinical scenarios, and provides clinical decision support integrated with existing workflows and EHR systems. Target users are hospitals, health screening centres, polyclinics, and diagnostic laboratories across Asia.
- DARA® Health Screening Automates health screening reports and risk analysis for primary care providers, health screening centres, and hospitals. The module generates complete reports in under 20 seconds with predictive analytics covering multiple chronic diseases, including cardiovascular disease, diabetes, hypertension, chronic kidney disease, and MAFLD, and supports risk projection up to 10 years before clinical diagnosis.
- DARA® Result Interpretation Digitises the result interpretation workflow for specialists, replacing manual processes such as printing, scanning, emailing, faxing, and courier delivery of results. Features include prioritisation of requests, physician notes integration, DRP and treadmill test interpretation, and real-time status tracking. Target users are specialist physicians and diagnostic laboratories handling high volumes of test results.
- DARA® Referral Digitises the referral workflow between clinics and specialists, enabling digital referral letter preparation, specialist request routing by network or insurance panel, referral progress tracking in real time, and secured sharing of consented patient health data. Target users are primary care clinics and specialist networks managing inter-provider referrals.
- HealthVector® Diabetes A regulatory-approved (HSA Class B SaMD) digital twin analysis software that provides a 3-year risk estimate for chronic kidney disease (CKD) stage 3A+ in adult patients aged 20-80 with Type 2 diabetes, using metabolic flux analysis and mechanistic physiological modelling without requiring specialised testing. Target users are endocrinologists, nephrologists, internal medicine specialists, and hospitals managing large Type 2 diabetes populations.
Quantifiable outcome
- Reduce manual report generation by 90%
- +4 more outcomes
Companies that use Mesh Bio
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
Mesh Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature5 records
Mesh Bio partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, strategic and minor.
- Singapore General Hospital (SGH)coreImplementation pilot for HealthVector Diabetes at Singapore General Hospital for potential clinical adoption. Validation study led by SGH using SingHealth Diabetes Registry dataset.
- Tan Tock Seng Hospital (TTSH)coreImplementation pilot for HealthVector Diabetes at Tan Tock Seng Hospital with Associate Professor Rinkoo Dalan co-leading research study. Supported by NHIC I2Adopt Grant.
- National Healthcare Group (NHG) Centre for Medical Technologies and Innovations (CMTi)strategicNHG CMTi facilitated partnership between Mesh Bio and TTSH for HealthVector Diabetes implementation pilot.
- PT PramitacoreMOU signed for adoption of Mesh Bio's predictive analytics software across more than 30 diagnostic centers in Indonesia. Partnership aims to deliver personalized preventive care and disease risk insights.
- MultiOmic HealthstrategicPartnership to conduct observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease. UK-based AI-enabled drug discovery company.
- Startup CreasphereminorMesh Bio became the first Asian start-up to join Startup Creasphere Batch 3 accelerator program, an international collaboration to pilot digital solutions.
Scale indicators5 records
Recent moves7 records
Expansion highlights4 records
Mesh Bio competitors and assessment
Company assessmentDirect peers
- Lark Health: US-based AI chronic disease prevention and management platform for diabetes, hypertension, and prediabetes. Direct peer: comparable AI-driven chronic-disease prediction platform, enterprise/payer GTM.
- Omada Health: US-based virtual care company using predictive analytics and digital coaching for diabetes, hypertension, and chronic disease prevention. Direct peer: same chronic-disease predictive analytics + virtual care model, employer/payer/provider GTM.
- WellDoc: US-based digital therapeutics platform focused on diabetes and cardiovascular chronic disease management using AI-driven coaching and analytics. Direct peer: similar diabetes/CVD focus, regulated SaMD positioning (FDA-cleared), enterprise B2B GTM.
- Glooko: Diabetes data management and analytics platform integrating devices and EHRs for clinicians and patients. Direct peer: comparable diabetes-focused SaaS with EHR integration, similar provider-and-patient analytics play.
- Biofourmis: Boston/Singapore-based AI health company focused on remote patient monitoring and predictive analytics for chronic conditions (heart failure, COPD, diabetes). Direct peer: same AI-driven chronic-disease prediction thesis, similar Southeast Asia presence, comparable enterprise provider and pharma customers.
- Holmusk: Singapore-headquartered digital health company building a behavioral health and chronic disease analytics platform using real-world clinical data. Direct peer: overlapping chronic-disease analytics category, similar Singapore/SEA base, comparable B2B SaaS model aimed at providers and pharma.
- DarioHealth: Global digital therapeutics company focused on diabetes, hypertension, and musculoskeletal chronic conditions. Direct peer: similar diabetes/CKD/chronic disease focus, B2B2C SaaS distribution.
Broad incumbents
- Tempus AI: US AI-driven precision medicine company applying AI to clinical and molecular data for disease prediction, diagnostics, and pharma research. Broad incumbent: comparable AI analytics for chronic disease + pharma/biomarker focus, but at much larger scale.
- Verily (Alphabet): Alphabet-owned precision health company applying AI, digital twins, and real-world evidence to chronic disease research and care. Broad incumbent: deeper pockets, broader portfolio, but overlapping chronic-disease + digital-twin thesis with global scale.
Regional players
- Doctor Anywhere: Singapore-headquartered regional telehealth and chronic care platform serving Southeast Asia. Regional peer: same Singapore base and SEA healthcare provider market, overlapping chronic-disease management themes though delivered more via telehealth than analytics-first.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Mesh Bio social profiles
Digital presenceMesh Bio compliance and trust
Trust signalCompliance3 records
Mesh Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mesh Bio leadership team
Management profileNumber of profiles
Profiles13 records
Mesh Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mesh Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mesh Bio
What does Mesh Bio do?
Mesh Bio sells an AI-powered health intelligence software platform called DARA® that delivers predictive analytics, risk stratification, and clinical workflow automation to healthcare providers for chronic disease management. The company also offers HealthVector® Diabetes, an HSA-approved Class B Software as a Medical Device that predicts 3-year onset risk of chronic kidney disease in Type 2 diabetes patients using metabolic digital twin technology.
Is Mesh Bio a public or private company?
Mesh Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mesh Bio founded?
Mesh Bio was founded in 2018. It employs 11 to 50 people.
Where is Mesh Bio based?
Mesh Bio is headquartered in Bukit Merah, Singapore, in the Asia region.
How does Mesh Bio make money?
Two revenue lines are on record. Software/SaaS Subscription is the primary driver. The others are regulatory-approved Medical Device.
Who are Mesh Bio's main competitors?
Direct peers on record are Lark Health, Omada Health, WellDoc, Glooko, Biofourmis, Holmusk and DarioHealth. Broad incumbents are Tempus AI and Verily (Alphabet). Doctor Anywhere is listed as a regional player.
Does Mesh Bio have an API?
No public API is recorded for Mesh Bio.
What industry is Mesh Bio in?
Mesh Bio's product category is Digital Health Analytics Software. Its primary akta.pro industry code is HLACAFAM, AI/Analytics for RPM (Risk Stratification, Alerts, Predictive), with a secondary code of HLACAPAD, Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension). Its NAICS code is 5132 and its SIC code is 8000.